ライフサイエンスコーパス: pharmacodynamic

1 d improving bacteriocin pharmacokinetics and pharmacodynamics.

2 model accounts for drug pharmacokinetics and pharmacodynamics.

3 recapitulating clinical pharmacokinetics and pharmacodynamics.

4 eir assembly, stability, immunogenicity, and pharmacodynamics.

5 orbidities, and altered pharmacokinetics and pharmacodynamics.

6 for understanding their pharmacokinetics and pharmacodynamics.

7 y and optimizing antibiotic pharmacokinetics/pharmacodynamics.

8 ndin exhibiting distinctive pharmacokinetics/pharmacodynamics.

9 y, antitumor efficacy, pharmacokinetics, and pharmacodynamics.

10 icles provided improved pharmacokinetics and pharmacodynamics.

11 o enhance active ingredient pharmacology and pharmacodynamics.

12 results in great changes in pharmacology and pharmacodynamics.

13 ude understanding of mechanism of action and pharmacodynamics.

14 n be exploited to comprehensively understand pharmacodynamic actions, although proper frameworks to r

15 e, compound 39 (AM-0466) demonstrated robust pharmacodynamic activity in a NaV1.7-dependent model of

16 s across multiple species, and to assess the pharmacodynamic activity of a miR-29b mimic (remlarsen)

17 and progression-free survival and determine pharmacodynamic activity of AZD1775 in surrogate tissues

18 Monitoring the pharmacodynamic activity of cancer immunotherapy with no

19 Pharmacokinetic-pharmacodynamic activity of compound 42 in a TNF-induced

20 OR biomarkers can be used for monitoring the pharmacodynamic activity of HDAC inhibitors.

21 systemic exposure and no measurable systemic pharmacodynamic activity.

22 l, overall survival, and pharmacokinetic and pharmacodynamic analyses (primary results reported elsew

23 l (patho)physiology, yet pharmacokinetic and pharmacodynamic analyses require multi-organ systems lin

24 ecessary on the basis of pharmacokinetic and pharmacodynamic analyses suggesting that the previous br

25 Pharmacodynamic analyses were performed at 8 time points

26 iology, conduct thorough pharmacokinetic and pharmacodynamic analyses, discover translatable biomarke

27 The pharmacokinetic or pharmacodynamic analysis did not indicate a relationship

28 ) In this study, using a combination of drug pharmacodynamic analysis in human study participants, di

29 An LVEF pharmacokinetic or pharmacodynamic analysis of the pooled data set was perf

30 ment and inhibition of fibrosis, we measured pharmacodynamic and disease-related end points.

31 dies frequently require biopsy specimens for pharmacodynamic and molecular biomarker analyses, includ

32 These human pharmacodynamic and pharmacokinetic data, although limit

33 ied selective KOP-r antagonists have unusual pharmacodynamic and pharmacokinetic properties (slow dev

34 s are required to investigate pharmacologic, pharmacodynamic and physical properties of FBIC.

35 um or tissue eosinophil counts, evolved as a pharmacodynamic and predictive biomarker for the efficac

36 However, pharmacodynamic and safety studies are necessary to furt

37 with the compound, including pharmacokinetic/pharmacodynamics and efficacy assessment by TSPO autorad

38 tolide field focusing on differentiating the pharmacodynamics and especially the toxicology of the ma

39 n, FQ plasma and tissue pharmacokinetics and pharmacodynamics and is based on extensive in vitro and

40 Assessment of safety, pharmacodynamics and nasal allergic reactivity following

41 ase2 inhibitor that possesses both favorable pharmacodynamics and pharmacokinetic (PK) parameters, in

42 We explored the pharmacodynamics and pharmacokinetics in a rabbit model.

43 cules within condensates contributes to drug pharmacodynamics and that further understanding of this

44 We emphasize the diversity in pharmacodynamics and toxicity of the macrolides and keto

45 and evolving microbiologic, pharmacokinetic-pharmacodynamic, and clinical data indicated that the pr

46 se breakpoints are based on pharmacokinetic, pharmacodynamic, and clinical outcome data from adults a

47 Safety, pharmacokinetic, pharmacodynamic, and exploratory efficacy outcomes were

48 and the schedule, safety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398,

49 ely estimating the correct pharmacokinetics, pharmacodynamics, and drug interaction effects.

50 We assessed the safety, pharmacokinetics, pharmacodynamics, and efficacy of lumacaftor and ivacaft

51 rial, we evaluated the safety, tolerability, pharmacodynamics, and efficacy of lumacaftor/ivacaftor c

52 We assessed pharmacokinetics, pharmacodynamics, and efficacy of the pan-PI3K inhibitor

53 part B (to assess safety, pharmacokinetics, pharmacodynamics, and efficacy).

54 o characterize the safety, pharmacokinetics, pharmacodynamics, and efficacy, and to identify the reco

55 ounds with improved selectivity, appropriate pharmacodynamics, and efficacy.

56 the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of mavorixafo

57 ing drug pharmacokinetics, measuring therapy pharmacodynamics, and providing a marker of therapeutic

58 dynamics with antibody pharmacokinetics and pharmacodynamics, and will be generally applicable to fo

59 The advantages of alternative pharmacodynamic approaches in post-traumatic minimally c

60 SC) administration of nanochelators improves pharmacodynamics, as evidenced by a 7-fold increase in e

61 del and in humans, supporting the use of the pharmacodynamic assay in clinical trials as a potentiall

62 strated on-target Pim activity in an in vivo pharmacodynamic assay with significant inhibition of BAD

63 Pharmacodynamic assessment of the systemic effect of inh

64 Pharmacodynamic assessments were Cogstate cognitive test

65 Pharmacodynamic assessments were repeated 1 to 6 months

66 rations (pharmacokinetics) and drug actions (pharmacodynamics), available data from clinical trials,

67 To become a reliable pharmacodynamic biomarker for ALS multicenter trials, TS

68 efore, TRPV2 merits further exploration as a pharmacodynamic biomarker for leukemia patients (with pu

69 get in AD and identify CSF oAbeta as a novel pharmacodynamic biomarker for use in trials of anti-Abet

70 We also identified MEIS1 as a potential pharmacodynamic biomarker of treatment response with MI-

71 nuclear ribonucleoprotein A1 (hnRNP-A1) as a pharmacodynamic biomarker of type I PRMT inhibition.

72 This pharmacodynamic biomarker provides important information

73 However, a pharmacodynamic biomarker to demonstrate that a biologic

74 Hsp70 drug discovery by providing XIAP as a pharmacodynamic biomarker.

75 cing therapeutic will require an appropriate pharmacodynamic biomarker: a practical and robust method

76 f DNA repair that provide new predictive and pharmacodynamic biomarkers for these targeted therapies.

77 ll as improved lung function and reduced key pharmacodynamic biomarkers in bronchial tissues.

78 entified substrates that can serve as robust pharmacodynamic biomarkers of HtrA1 activity.

79 This study aimed to identify pharmacodynamic biomarkers of miR-29 in mouse skin, to t

80 ith limited ability to evaluate conventional pharmacodynamic biomarkers of response.

81 atory histological, blood-based, and imaging pharmacodynamic biomarkers that may reflect meaningful t

82 p develop combination strategies or identify pharmacodynamic biomarkers to support the clinical devel

83 or haemophagocytic lymphohistiocytosis), and pharmacodynamic biomarkers.

84 glucocorticoids affected two major groups of pharmacodynamic biomarkers.

85 tives were to assess the pharmacokinetic and pharmacodynamic characteristics and safety of fitusiran.

86 hydroartemisinin and has pharmacokinetic and pharmacodynamic characteristics compatible with a single

87 nformation regarding the pharmacokinetic and pharmacodynamic characteristics of 1, it was demonstrate

88 The pharmacodynamic characteristics of CPP-115 remain to be

89 d sufficient preclinical pharmacokinetic and pharmacodynamic characteristics which allowed for in viv

90 antimicrobial activity, pharmacokinetics and pharmacodynamics, clinical indications, and safety profi

91 lamanid, and linezolid), pharmacokinetic and pharmacodynamic considerations, preventive strategies (s

92 new understanding of the pharmacokinetic and pharmacodynamic contributors to effective therapy, the p

93 Pharmacokinetic-pharmacodynamic curves showed a linear relationship betw

94 Nonetheless, the trends in safety and pharmacodynamic data support further clinical developmen

95 On the basis of safety and pharmacokinetic-pharmacodynamic data, the avadomide RP2D was established

96 Pharmacokinetics-pharmacodynamics data show a steady-state concentration

97 We found a significant pharmacodynamic difference between morphine and methadon

98 The stark pharmacodynamic differences were confirmed upon pharmaco

99 strates that tralokinumab prevents the IL-13 pharmacodynamic effect by binding to IL-13 helices A and

100 omarkers for disease severity and apremilast pharmacodynamic effect in psoriasis patients.

101 eripheral insulin changes, conclude that the pharmacodynamic effect is centrally driven.

102 terogeneity in EGFR activity, as well as the pharmacodynamic effect of a radionuclide-labeled EGFR in

103 Pharmacodynamic effect of AZD9412 was confirmed using IF

104 ovel assay to measure the intended molecular pharmacodynamic effect of decitabine therapy can therefo

105 link between disease severity, drug-induced pharmacodynamic effects and response status in human tri

106 ful for the assessment of GSK3368715 induced pharmacodynamic effects in blood and tumors that can be

107 Safety, tolerability, pharmacodynamic effects of cilofexor (serum C4 [7alpha-h

108 troscopy studies that characterize the acute pharmacodynamic effects of CPP-115 with additional dose-

109 In Cohort 4, observed pharmacodynamic effects of RMD were reduced proportions

110 dingly, in this review, we summarize the key pharmacodynamic effects of SGLT2 inhibitors and the clin

111 We examined the pharmacodynamic effects of SNF472, a calcification inhib

112 The pharmacodynamic effects of soticlestat were characterize

113 However, the pharmacodynamic effects of this approach on blood thromb

114 e plasma viremia or unspliced CA-RNA despite pharmacodynamic effects on CD4 + T cells.

115 Pharmacodynamic effects were assessed on the last day of

116 Pharmacodynamic effects were measured as P2Y(12) reactio

117 The overall long-term pharmacodynamic effects, assessed by hemoglobin A1c (HbA

118 een linked to more sustained and deleterious pharmacodynamic effects.

119 In vivo pharmacodynamic efficacy was evaluated using Morris Wate

120 etween scores and glycemic traits as well as pharmacodynamic end points, adjusting for age, sex, race

121 ng point for a future efficacy trial using a pharmacodynamic endpoint.

122 Further studies designed to examine pharmacodynamic endpoints, such as ovulation, when intra

123 (Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coat

124 nd medication-like duration of action in rat pharmacodynamic experiments.

125 doperoxide with combined pharmacokinetic and pharmacodynamic features that overcome the liabilities o

126 The clinical implications of these pharmacodynamic findings warrant investigation in an ade

127 developed a computational model of cisplatin pharmacodynamics following EBUS-TBNI.

128 ectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compounds.

129 ed understanding of the pharmacokinetics and pharmacodynamics for current and future antimicrobials i

130 As pharmacodynamics for the approved dose are optimized onl

131 e course of eculizumab using pharmacokinetic/pharmacodynamic-guided dosing, requiring a median of 11

132 plasma levels were very low, suggesting that pharmacodynamic (i.e., pseudoirreversible binding to mu

133 Pharmacodynamic improvements are evolving to allow biasi

134 ases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenogra

135 cell, IC(50,free) = 6.2 nM) and good in vivo pharmacodynamics in a calcium ionophore-stimulated rat m

136 l evaluated apremilast efficacy, safety, and pharmacodynamics in adults with moderate to severe atopi

137 netics, safety, and efficacy in children and pharmacodynamics in individuals naive to antiretroviral

138 or activity; exploratory objectives included pharmacodynamics in timed paired tumor biopsies.

139 entified active chemical species and resolve pharmacodynamic interactions within other chemically com

140 ween lipid structure/configuration and siRNA pharmacodynamics is unclear.

141 real-time screening technologies to identify pharmacodynamics/-kinetics of single and combined drugs

142 rum pharmacokinetics (HVTN 104) and in vitro pharmacodynamics (LANL CATNAP database).

143 nstrate that MYC suppression is an important pharmacodynamic marker of BET bromodomain inhibitor resp

144 ling coupled with proteomics uncovered novel pharmacodynamic markers and cellular pathways regulated

145 However, there is limited information about pharmacodynamic markers of response or mediators of de n

146 n this study, we developed a pharmacokinetic/pharmacodynamic mathematical model that identifies in si

147 suggest that knemometry is a more sensitive pharmacodynamic measure of systemic effects of ICSs than

148 Safety, the side-effect profile, and pharmacodynamic measures (PCSK9 level, LDL cholesterol l

149 ty, side-effect profile, pharmacokinetic and pharmacodynamic measures, and changes in levels of lipid

150 but differences in underlying aetiology and pharmacodynamics might differentially affect response to

151 inhibition in a mouse IL-12-induced IFNgamma pharmacodynamic model as well as efficacy in an IL-23 an

152 ach to establish an in vitro pharmacokinetic/pharmacodynamic model to describe how the concentration

153 which was advanced into a target engagement pharmacodynamic model where it exhibited robust reversal

154 esian network modeling and a pharmacokinetic-pharmacodynamic model.

155 Pharmacokinetic/pharmacodynamic modeling estimated a minimum inhibitory

156 We extend existing pharmacokinetic/pharmacodynamic modeling methods to simulate the treatme

157 Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy

158 y: a breakpoint supported by pharmacokinetic/pharmacodynamic modeling that bisected the wild-type Ent

159 Using pharmacokinetic-pharmacodynamic modelling and mouse-human bridging analy

160 Current pharmacokinetic-pharmacodynamic models mainly focus on the antiangiogeni

161 and brain Abeta(40) levels in rat and monkey pharmacodynamic models.

162 Pharmacodynamic monitoring of belatacept was performed b

163 alation study, guided by pharmacokinetic and pharmacodynamic observations, evaluated whether simultan

164 study investigated the safety, efficacy, and pharmacodynamics of a selective BTK inhibitor acalabruti

165 safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with sympto

166 0263) assessed the safety, tolerability, and pharmacodynamics of ASP4345 in patients with schizophren

167 he purpose of this study was to document the pharmacodynamics of CO2 for MBF using prospective end-ti

168 tudies identify a novel process by which the pharmacodynamics of cocaine are derived in vivo, and thu

169 oroestradiol PET imaging would elucidate the pharmacodynamics of combination HDACIs and endocrine the

170 safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincri

171 safety, tolerability, pharmacokinetics, and pharmacodynamics of iscalimab in healthy subjects and rh

172 less, insights into the pharmacokinetics and pharmacodynamics of LAmB continue to evolve and can be u

173 The safety, pharmacokinetics, and pharmacodynamics of MMV390048 support its further develo

174 This new insight into the pharmacodynamics of mTOR inhibitors in regulation of neu

175 to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001, NCT028682

176 ercellular drug transfer that contributes to pharmacodynamics of neighboring cells.

177 efined as the day of injection, and thus the pharmacodynamics of single injections could be assessed;

178 We assessed the safety and pharmacodynamics of the vaccine in patients with coeliac

179 mechanisms of action of antibiotics and the pharmacodynamics of their interaction with bacteria tell

180 emporal tissue pharmacokinetics and in vitro pharmacodynamics of these FQs.

181 BIO 300 and a reasonable illustration of the pharmacodynamics of this radiation countermeasure.

182 safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with JNJ-42165279 in subje

183 sed the safety, tolerability, adherence, and pharmacodynamics of two doses of NaHCO(3) over 28 weeks

184 absorption, excretion, pharmacokinetics, and pharmacodynamics of various anticoagulants.

185 results in altered drug pharmacokinetics and pharmacodynamics or formation of toxic metabolites which

186 ve biomarkers of disease and of HTT lowering pharmacodynamic outcomes have brought these potential th

187 ficacy was reported, only pharmacokinetic or pharmacodynamic outcomes were reported, or if ten or few

188 ent binding to BTK and has been applied as a pharmacodynamic parameter in clinical studies of BTK inh

189 Pharmacokinetic/pharmacodynamic parameters were simultaneously fitted in

190 mune function and opioid pharmacokinetic and pharmacodynamic parameters, structural and behavioral in

191 nt and physiologically based pharmacokinetic/pharmacodynamic (PBPK/PD) modeling at the example of RLT

192 Pharmacodynamic (PD) analysis referenced stroma/host cel

193 safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and behavioral effects of a novel g

194 rugs of abuse and toxins can occur either by pharmacodynamic (PD) approaches based on bioreceptor.dru

195 or real time in vivo BTK RO measurement as a pharmacodynamic (PD) biomarker for clinical drug develop

196 ine pool size, whose change might reveal the pharmacodynamic (PD) effect of drugs targeting this canc

197 in-penetrant ATM inhibitors that have robust pharmacodynamic (PD) effects consistent with ATM kinase

198 , tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) effects of single BIIB059 doses in

199 Other objectives were to characterize the PK/pharmacodynamic (PD) relationship, correlate biomarkers

200 ry - we investigate the pharmacokinetic (PK)-pharmacodynamic (PD) relationships that underlie the abi

201 Stochastic PK/pharmacodynamic (PD) simulations were carried out to eva

202 Compound 12 was evaluated in a mouse pharmacodynamics (PD) model and demonstrated a 56% incre

203 ty, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of the human anti-C5 monoclonal an

204 evaluated the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antileukemic acti

205 s study evaluated the pharmacokinetics (PK), pharmacodynamics (PD), clinical efficacy and safety of e

206 imum tolerated dose (MTD), pharmacokinetics, pharmacodynamics (PD), efficacy, and safety of duvelisib

207 Analyses of drug pharmacokinetics (PKs) and pharmacodynamics (PDs) performed in animals are often no

208 s received the selected dose on the basis of pharmacodynamic, pharmacokinetic, safety, and activity d

209 We assessed the pharmacodynamics, pharmacokinetics, preliminary efficacy

210 Through use of this pharmacokinetic-pharmacodynamic (PK-PD) approach we demonstrate that the

211 Pharmacokinetic/pharmacodynamic (PK/PD) analysis in patients with isavuc

212 describe a semi-mechanistic pharmacokinetic-pharmacodynamic (PK/PD) model to investigate observed an

213 integrating within-host pharmacokinetic and pharmacodynamic (PK/PD) models with mathematical models

214 e therefore assessed whether pharmacokinetic/pharmacodynamic (PK/PD) parameters could predict 2-month

215 The pharmacokinetic/pharmacodynamic (PK/PD) relationship as well as pulmonar

216 A dynamic population pharmacokinetic/pharmacodynamic (PK/PD) simulation model including rifam

217 sure, determined by the pharmacokinetics and pharmacodynamics (PK/PD) after intravenous (IV) antibiot

218 ategies, such as population pharmacokinetics/pharmacodynamics (PK/PD) and systems biology/pharmacolog

219 tem to evaluate the temporal pharmacokinetic/pharmacodynamic (PKPD) relationship for terfenadine.

220 To determine the pharmacokinetics and pharmacodynamics (PKPD) of ciprofloxacin prophylaxis in

221 -effective-concentration (MEC, 25 ng/mL) and pharmacodynamic (plasma HIV RNA) parameters were assesse

222 SWE101) has an excellent pharmacokinetic and pharmacodynamic profile in rats and enables the investig

223 The pharmacodynamic profile of lanadelumab was assessed by m

224 ents, differences in the pharmacokinetic and pharmacodynamic profile of the agent can occur.

225 cin challenge studies; despite this improved pharmacodynamic profile, spontaneous cough frequency did

226 CD-1 mice to study their pharmacokinetic and pharmacodynamic profile.

227 o its efficacy and optimized pharmacokinetic/pharmacodynamic profile.

228 bitors can have a beneficial pharmacokinetic/pharmacodynamics profile but are still often avoided due

229 on phase on the basis of pharmacokinetic and pharmacodynamic profiles and demonstrated efficacy.

230 more favorable pharmacokinetic and antitumor pharmacodynamic profiles in vivo than that of native TRA

231 The factor VIII pharmacodynamic profiles reflected cellular turnover in

232 um tolerated dose (MTD), pharmacokinetic and pharmacodynamic profiles, safety, and clinical activity

233 native physicochemical, pharmacokinetic, and pharmacodynamic profiles.

234 On the basis of safety, pharmacokinetic, and pharmacodynamic profiling, the RP2D was defined as 800 m

235 molecule cancer therapeutics such that their pharmacodynamic properties are altered.

236 e(II) reactivity and the pharmacokinetic and pharmacodynamic properties of 1,2,4-trioxolane antimalar

237 is required to study the pharmacokinetic and pharmacodynamic properties of antisense oligonucleotides

238 Here we examined the pharmacodynamic properties of chronic morphine in mice f

239 We determined the pharmacokinetic and pharmacodynamic properties of MVT-602 (doses 0.01 and 0.

240 tal tool to evaluate the pharmacokinetic and pharmacodynamic properties of selected phytocannabinoids

241 has highlighted unusual pharmacokinetic and pharmacodynamic properties of these compounds, including

242 e safety, tolerability, pharmacokinetic, and pharmacodynamic properties of voxelotor and established

243 AMPs exhibit pharmacodynamic properties that reduce the evolution of

244 ections, then (i) antibiotics with different pharmacodynamic properties would be similarly effective,

245 er, challenges regarding target specificity, pharmacodynamic properties, efficacy and safety remain.

246 by chance an anti-CD20 mAb with equilibrated pharmacodynamic properties, the reinforcement of some of

247 ng strategies to improve pharmacokinetic and pharmacodynamic properties.

248 r bacterial biofilms; postantibiotic effect; pharmacodynamic properties; and in vitro and in vivo eff

249 sign of covalent inhibitors with appropriate pharmacodynamics properties coupled with limited unwante

250 that might be exploited for therapeutic and pharmacodynamic purposes.

251 homeostasis and to best design and interpret pharmacodynamic readouts for HTT lowering therapeutics.

252 lyglutamine-expanded proteins as well as the pharmacodynamics readouts to monitor their efficacy in p

253 to analyze the in vivo pharmacokinetics and pharmacodynamics relationship of KDM1A inhibitors, as ha

254 is on the treated set]), and pharmacokinetic-pharmacodynamic relationships (descriptive analyses).

255 ms of efficacy, with similar pharmacokinetic-pharmacodynamic relationships as those seen in adults, a

256 Pharmacokinetic/pharmacodynamic relationships of dabigatran were similar

257 tro-in vivo correlations and pharmacokinetic-pharmacodynamic relationships to optimize candidate sele

258 , schedule and corresponding pharmacokinetic/pharmacodynamic relationships.

259 rocessing events and defines pharmacokinetic-pharmacodynamic relationships.

260 ion of h-alpha-Gal A mRNA showed a sustained pharmacodynamic response and efficacy in Fabry mice mode

261 protocol could differentiate phenotypic and pharmacodynamic responses to Selumetinib (0-3uM).

262 these biomarkers show promise for monitoring pharmacodynamic responses to sulforaphane in both health

263 of testing issues, murine and human in vivo pharmacodynamics, safety of off-label doses, and treatme

264 le, we review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB in a wide

265 were estimated through pharmacokinetics and pharmacodynamics simulation, IFE outcome was best predic

266 Pharmacodynamic studies demonstrated substantial inhibit

267 Pharmacodynamic studies have suggested superiority of th

268 Pharmacokinetic-pharmacodynamic studies identify fAUC0-24/MIC ratio as t

269 esent method will enable pharmacokinetic and pharmacodynamic studies of p-XSC in both clinical and pr

270 Pharmacodynamic studies showed preliminary evidence of A

271 Exploratory pharmacodynamics studies including changes in diffusion-

272 ristic drug, SAL, during pharmacokinetic and pharmacodynamics studies.

273 lent activity in an IL-2/IL-23-induced mouse pharmacodynamic study and demonstrated biologic-like eff

274 randomized, double-blind, placebo-controlled pharmacodynamic study conducted in patients undergoing p

275 d demonstrated potent target inhibition in a pharmacodynamic study in leukemic mice.

276 Finally, a pharmacokinetic/pharmacodynamic study was conducted in cynomolgus monkey

277 ase of insulin-like growth factor-1 in a dog pharmacodynamic study.

278 on, including a comparative pharmacokinetics/pharmacodynamics study that is usually conducted in heal

279 ive pathogens include (1) a pharmacokinetics/pharmacodynamics study to evaluate the impact of vancomy

280 8 patients enrolled in a pharmacokinetic and pharmacodynamic substudy from 4 phase 2 trials, circulat

281 rated cellular PTX pharmacokinetics with PTX pharmacodynamics successfully predicted effects of exoso

282 ical data on vancomycin pharmacokinetics and pharmacodynamics suggest a reevaluation of current dosin

283 rapy in melanoma patients occur rapidly with pharmacodynamic T cell responses detectable in blood by

284 Antibiotic pharmacodynamic target attainment rates likely were not

285 the probability of attaining pharmacokinetic-pharmacodynamic target goals is essential to guide optim

286 The pharmacodynamic target of fT greater than 1 x minimum in

287 of antibiotic dosing regimens regardless of pharmacodynamic target.

288 However, pharmacodynamic targets associated with positive patient

289 only does the probability of pharmacokinetic/pharmacodynamic targets need to be taken into account bu

290 ty of target attainment was calculated using pharmacodynamic targets of percentage of time that free

291 physical function, frailty, disability, and pharmacodynamics that all merit further investigation.

292 of fMRI affords detailed mapping of regional pharmacodynamics that underlie mechanisms of pain suppre

293 We compare the pharmacokinetics and pharmacodynamics to the clinical comparator progesterone

294 Recent data on polymyxin pharmacokinetics, pharmacodynamics, toxicity, and clinical outcomes sugges

295 including discussions of pharmacokinetic and pharmacodynamic trials, spectrum of activity and preclin

296 macology relies on ligands that change their pharmacodynamics upon photoisomerization.

297 human skin can be successfully cultured for pharmacodynamic use up to and beyond 9 days without any

298 a combination of MIC values, pharmacokinetic/pharmacodynamic values, and clinical outcome data.

299 Efficacy and pharmacodynamics were secondary end points.

300 , with greatly improved pharmacokinetics and pharmacodynamics when compared with recombinant IL-2 to